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Production of influenza virus in animal cells has emerged as an alternative to conventional platforms such as 
egg-based production system. Animal cells, especially MDCK and VERO cell lines, are widely used as the 
primary production cell for influenza virus vaccine because of their high susceptibility to infection with various 
influenza viruses. Recently, a robust and reliable purification process was successfully developed for the 
production of quadri-valent HA proteins (from two strains of the type A virus and two strains of the type B virus) 
by using animal cell-based production system in Green Cross Corp., Korea. The UF/DF process, Benzonase 
treatment at high temperature as well as column chromatography strategy was optimized to maximize the final 
HA production yields. Benzonase treatment was conducted to reduce in hcDNA (host cell DNA) because hcDNA 
was main impurity for cell-based influenza virus vaccine. A simple and stable UF/DF process has been tested 
with membrane molecular weight cutoffs of 100 and 300 kDa as well as 0.2 and 0.45 um microfiltration 
membrane. Anion exchange chromatography (AEC) and size exclusion chromatography (SEC) were selected 
for acceptable reduction in hcDNA and HCP. AEC was used to separate hcDNA from virus at a salt 
concentration of 0.5 M sodium chloride. The HA yield through AEC & SEC combination process was sufficiently 
achieved under specific purification process condition. Overall, the amount of residual hcDNA was reduced to 
an acceptable level (10ng/dose) and the increased HA yield was maintained throughout the whole process. The 
performance, productivity and scalability of the purification process were successfully demonstrated in over 30 
GMP batches using 4 different influenza virus strains. 
 
